» Articles » PMID: 23946320

De Novo Generation of Short Antimicrobial Peptides with Enhanced Stability and Cell Specificity

Overview
Date 2013 Aug 16
PMID 23946320
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Though antimicrobial peptides (AMPs) show great potential as novel antibiotics, therapeutic applications are hindered by their low stability, toxicity and high manufacturing cost. Various chemical modification strategies are employed to overcome these problems. However, chemical modifications often significantly increase the manufacturing cost of AMPs with only limited pharmacokinetic advantages. Therefore, we developed AMPs with enhanced stability and cell specificity that can be economically produced.

Methods: Peptides were designed by systematic amino acid arrangement without the incorporation of both non-natural amino acids and peptidomimetics. Antimicrobial activities were measured against Gram-positive bacteria, Gram-negative bacteria and fungi by MIC evaluation under both standard and physiologically relevant conditions. Cytotoxicity towards human cells was evaluated to verify selective antimicrobial activity. The antibacterial mechanism of the peptides was elucidated by β-galactosidase assay and scanning electron microscopy.

Results: Among the designed peptides, GNU6 and GNU7 showed potent antimicrobial activity against bacteria and fungi and maintained their activity in the presence of 150 mM NaCl and 10% serum. These peptides were not digested by exposure to trypsin, chymotrypsin and aureolysin for up to 12 h and showed potent antimicrobial activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Moreover, they did not affect the viability of erythrocytes, keratinocytes and fibroblasts up to 128 mg/L. A membrane permeabilization assay and scanning electron microscopy analysis showed that GNU6 and GNU7 compromised membrane integrity and function in microorganisms.

Conclusions: This study suggests that GNU6 and GNU7 might overcome serious problems that currently prevent the clinical use of AMPs and be developed as novel antimicrobial agents.

Citing Articles

Cliotide U1, a Novel Antimicrobial Peptide Isolated From Leaves.

Taheri M, Seyedjavadi S, Goudarzi M, Ebrahimipour G, Hashemi A Bioinform Biol Insights. 2025; 19:11779322251315291.

PMID: 39886350 PMC: 11780632. DOI: 10.1177/11779322251315291.


A Tachyplesin Antimicrobial Peptide from Theraphosidae Spiders with Potent Antifungal Activity Against .

Michira B, Wang Y, Mwangi J, Wang K, Asmamaw D, Tadese D Microorganisms. 2025; 12(12.

PMID: 39770850 PMC: 11728142. DOI: 10.3390/microorganisms12122648.


Immunomodulatory peptides: new therapeutic horizons for emerging and re-emerging infectious diseases.

Chatterjee D, Sivashanmugam K Front Microbiol. 2025; 15:1505571.

PMID: 39760081 PMC: 11695410. DOI: 10.3389/fmicb.2024.1505571.


Optimization and Stability Assessment of Antimicrobial Peptide MaltAtt-1 in GS115 for the Control of Pine Wood Nematode.

Jiang D, Xu X, Wang Z, Yu C, Wang Z, Xu Y Int J Mol Sci. 2024; 25(16).

PMID: 39201243 PMC: 11354690. DOI: 10.3390/ijms25168555.


Engineering Enhanced Antimicrobial Properties in α-Conotoxin RgIA through D-Type Amino Acid Substitution and Incorporation of Lysine and Leucine Residues.

Wang M, Liao Z, Zhangsun D, Wu Y, Luo S Molecules. 2024; 29(5).

PMID: 38474693 PMC: 10935098. DOI: 10.3390/molecules29051181.